Pink Pony Peptides Warned for Unapproved Peptide Drugs
Summary
The FDA reviewed the website of Lovega LLC dba Pink Pony Peptides (Wellington, FL) in December 2025 and determined that the firm is marketing three products—GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water—as unapproved new drugs in violation of sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act. The agency is particularly concerned because injectable products bypass the body's natural defenses and can cause serious or life-threatening conditions. The firm has been given fifteen working days to respond in writing with specific corrective steps or face regulatory or legal action including seizure and injunction.
About this source
FDA Warning Letters are public notifications to firms the agency believes are significantly violating FDA regulations. Common triggers include Current Good Manufacturing Practice violations, unauthorized drug claims, substandard clinical trial conduct, unapproved marketing, and tobacco sales to minors. Letters require a written response within 15 working days. Around 75 letters land each month across drug manufacturers, medical device makers, tobacco retailers, and dietary supplement companies. Watch this if you run a regulated manufacturing operation, advise on FDA compliance, defend companies in enforcement matters, or track quality-system failures that precede recall events. GovPing publishes each letter with the recipient, agency division, and cited violations.
What changed
FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter to Lovega LLC dba Pink Pony Peptides for offering three products—GLP-2 TZ, GLP-3 RT, and Bacteriostatic Water—for sale as unapproved new drugs. The agency found that despite labeling stating the products are for "laboratory research purposes only" and "[n]ot for human consumption," the marketing claims on the firm's website demonstrate the products are intended for human use in the diagnosis, treatment, or prevention of disease, including claims about appetite suppression, fat loss, glucose control, and metabolic function. Because no FDA-approved applications are in effect for these products, their introduction into interstate commerce violates the FD&C Act.
Firms marketing peptide compounds, research chemicals, or similar products with therapeutic or disease-treatment claims should review their labeling and marketing materials carefully. FDA's position is clear: products intended for human use with drug claims require FDA approval, regardless of disclaimers on the label. A written response with corrective action plan is required within fifteen working days.
What to do next
- Notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations
- Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation
- If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Delivery Method: Via Email Product: Drugs Recipient: Susan Vega Lovega LLC dba Pink Pony Peptides 9314 Forest Hill Blvd 902
Wellington, FL 33411
United States
help@pinkponypeptides.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States
WARNING LETTER
March 31, 2026
RE: 721088
Susan Vega:
This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https://pinkponypeptides.com/ in December 2025. The FDA has observed that your website offers “GLP-2 TZ,” “GLP-3 RT,” and “Bacteriostatic Water” (hereinafter Pink Pony Peptides products) for sale in the United States. Based on our review, these products are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.
Despite statements on your product labeling marketing your products for “laboratory research purposes only” and “[n]ot for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or function of the body.
Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:
GLP-2 TZ
On the webpage https://pinkponypeptides.com/product/glp2/:
- “As a dual GIP and GLP-1 receptor agonist, Tirzepatide helps: o . . . Reduce appetite and increase satiety o . . . Enhance insulin sensitivity and glucose control o . . . Curb cravings without harsh stimulants o . . . Support fat loss over time with clinical precision Originally developed for type 2 diabetes, Tirzepatide has rapidly become a favorite among physicians and wellness experts for its dramatic body recomposition results and long-lasting appetite regulation.”
GLP-3 RT
On the webpage https://pinkponypeptides.com/product/glp3/:
- “As a GIP, GLP-1, and glucagon receptor agonist, Retatrutide offers three times the fat-fighting horsepower in one clean, clinical ride. This cutting-edge peptide has shown jaw-dropping results in clinical trials — helping the body torch fat, suppress appetite, regulate blood sugar, and even improve metabolic function better than its single-pathway competitors.” Bacteriostatic Water Your firm offers “Bacteriostatic Water” for sale alongside peptide products, which are drugs intended for injection and require reconstitution, including the two above-mentioned GLP products. The sale of these products together demonstrates that you intend for your “Bacteriostatic Water” to be used in combination for injection. Therefore, your “Bacteriostatic Water” is a drug.
Your Pink Pony Peptides products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Conclusion
The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.
This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.
Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “721088” in the subject line of the email.
Sincerely,
/S/
Tina Smith, M.S.
Captain, U.S. Public Health Service
Director
Office of Unapproved Drugs and Labeling Compliance
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
- ## Content current as of:
04/07/2026
Regulated Product(s)
- Drugs
CFR references
Mentioned entities
Related changes
Get daily alerts for FDA Warning Letters
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA Warning Letters publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.